Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jan;21(1):141-152.
doi: 10.1007/s40258-022-00762-9. Epub 2022 Sep 22.

Cost Effectiveness of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Patients with Knee Osteoarthritis

Kangho Suh  1 , Brian J Cole  2 , Andreas Gomoll  3 , Seung-Mi Lee  4 , Hangseok Choi  5 , Chul-Won Ha  6 , Hong Chul Lim  7 , Myung Ku Kim  8 , Gwi-Yeom Ha  5 , Dong-Churl Suh  5
Affiliations
Randomized Controlled Trial

Cost Effectiveness of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Patients with Knee Osteoarthritis

Kangho Suh et al. Appl Health Econ Health Policy. 2023 Jan.

Erratum in

Abstract

Objectives: The aim of this study was to assess the cost effectiveness of allogeneic umbilical cord blood-derived mesenchymal stem cells with sodium hyaluronate (hUCB-MSC) compared with microfracture in patients with knee cartilage defects caused by osteoarthritis (OA) in South Korea.

Methods: A partitioned survival model approach was taken consisting of five mutually exclusive health states: excellent, good, fair, poor, and death over a 20-year time horizon. Utility values were obtained from a randomized clinical trial. Cost data were extracted from a database provided by the Health Insurance Review & Assessment Service, and the utilization of healthcare services was estimated from an expert panel of orthopedic surgeons using a structured questionnaire. The incremental cost-effectiveness ratio (ICER) in terms of quality-adjusted life-years (QALY) was calculated. Deterministic and probabilistic sensitivity analyses were performed.

Results: In the base case, the incremental costs of US$14,410 for hUCB-MSC therapy along with its associated QALY gain of 0.857 resulted in an ICER of US$16,812 (₩18,790,773) per QALY (95% confidence interval [CI] US$13,408-US$20,828) when compared with microfracture treatment from a healthcare payer perspective. From a societal perspective, the ICER was US$268 (₩299,255) per QALY (95% CI -US$2915 to US$3784). When using a willingness-to-pay threshold of US$22,367/QALY, the probability of hUCB being cost effectiveness compared with microfracture was 99% from the healthcare payer perspective and 100% from the societal perspective.

Conclusions: The study demonstrated that hUCB-MSC therapy was cost effective compared with microfracture when treating patients with knee OA. These findings should inform health policy decision makers about considerations for cost-effective therapy for treating knee OA to ultimately enhance population health.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest to disclose.

Figures

Fig. 1
Fig. 1
Partitioned survival model with five health states
Fig. 2
Fig. 2
Tornado diagram of a one-way sensitivity analyses for hUCB-MSC therapy compared with microfracture. hUCB-MSC human umbilical cord blood-derived mesenchymal stem cells
Fig. 3
Fig. 3
Cost effectiveness scatterplot of hUCB-MSC therapy compared with microfracture. hUCB-MSC human umbilical cord blood-derived mesenchymal stem cells
Fig. 4
Fig. 4
Cost-effectiveness acceptability curves of hUCB-MSC therapy versus microfracture. hUCB-MSC human umbilical cord blood-derived mesenchymal stem cells
See this image and copyright information in PMC

References

    1. Neuprez AH, Kaux J-F, Kurth W, Daniel C, Thirion T, et al. Total joint replacement improves pain, functional quality of life, and health utilities in patients with late-stage knee and hip osteoarthritis for up to 5 years. Clin Rheumatol. 2020;39:861–871. doi: 10.1007/s10067-019-04811-y. - DOI - PubMed
    1. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M. The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73:1323–1330. doi: 10.1136/annrheumdis-2013-204763. - DOI - PubMed
    1. Hong JW, Noh JH, Kim D-J. The prevalence of and demographic factors associated with radiographic knee osteoarthritis in Korean adults aged ≥ 50 years: the 2010–2013 Korea National Health and Nutrition Examination Survey. PLoS ONE. 2020;15(3):e0230613. doi: 10.1371/journal.pone.0230613. - DOI - PMC - PubMed
    1. Lee S, Kim S-J. Prevalence of knee osteoarthritis, risk factors, and quality of life: the Fifth Korean National Health And Nutrition Examination Survey. Int J Rheum Dis. 2017;20(7):809–817. doi: 10.1111/1756-185X.12795. - DOI - PubMed
    1. Vitaloni M, Bemden AB-V, Contreras RMS, Scotton D, Bibas M, Quintero M, et al. Global management of patients with knee osteoarthritis begins with quality of life assessment: a systematic review. BMC Musculoskelet Disord. 2019;20:493. doi: 10.1186/s12891-019-2895-3. - DOI - PMC - PubMed

Publication types

LinkOut - more resources